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Introduction
This is an outline of the state of the art of
biomedical research as used to estimate the poten-
tial public health consequences oflong-term human
exposure to chemical agents in the environment. It
is a report on the ideas and research findings dis-
cussed at a conference held March 10-12, 1976, at
Pinehurst, N. C., sponsored by the National Insti-
tute of Environmental Health Sciences.
Current methods of estimating the human risk
from chronic exposure to low dose levels of chemi-
cal agents in the environment rely mainly on data
from experiments with laboratory animals. In these
experiments, animals are typically exposed to doses
low enough to minimize early deaths from acute
toxicity and yethigh enough to provide assurance of
detecting chronic effects, such as carcinogenicity.
Since the number ofanimals which can be employed
in testing any one chemical is limited, it is usually
necessary to expose the animals to dose levels far
above the anticipated range of human exposure in
order to be reasonably sure of detecting chronic ef-
fects.
The problem ofusing data on high-dose effects of
chemicals in animals to predict the low-dose effects
of these chemicals in humans is commonly known
as the low-dose extrapolation problem. This in-
cludes not only the complex biological problem of
inferring human response from data on animal re-
sponse, but also the biological and statistical prob-
lem of predicting effects in large populations ex-
posed to low dose levels from data on small popula-
tions exposed to high dose levels.
The metabolic reactions which occur when a
given chemical is administered to an animal depend
on a number offactors, including among others the
species, the specific genetic strain, the sex, and the
route by which the chemical is administered. The
same chemical can give rise to different metabolites
in different animals. Since the underlying
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mechanisms through which chemicals can induce
chronic diseases such as cancer are not completely
understood, it is currently not possible to relate
these metabolic differences in a quantitative way to
differences among species in the sensitivity to a
given chemical. However, experimental results in
laboratory animals are a guide to probable results in
humans.
Extrapolation from high dose levels to low dose
levels is also strongly affected by incompleteness in
current knowledge of chronic disease mechanisms.
Several biologically plausible statistical models
seem to fit the dose-response data more or less
equally well in the high-dose range and yet yield
markedly different estimates of risk at low dose
levels such as humans might encounter. These dif-
ferences in predictions are caused by different as-
sumptions about the relation between dose and re-
sponse. The exact nature of the relationship be-
tween dose and response is not known and is prob-
ably different for different classes of chemicals.
Although the scientific groundwork necessary for
a fundamental understanding of chronic toxicity is
incomplete, study of the practical regulatory prob-
lems cannot be deferred until all of the basic re-
search has been completed. Thousands of new
chemicals come into use each year, and the public
health hazards associated with both the new and the
existing chemicals need to be evaluated as quickly
and as comprehensively as possible.
The Pinehurst conference was an attempt to bring
together scientists engaged in basic and applied
biomedical research on the health effects of chemi-
cals in the environment, regulatory staff members,
and representatives of industry, public interest
groups, and the scientific press.
Early and Quick Indicators
of Carcinogenicity:
Presumptive Tests
The first step in "extrapolation" begins with de-
termining whether or not a substance is car-
February 1978 173cinogenic. The hope is that relatively rapid tests will
become available for determining carcinogenicity
and mutagenicity. These tests, involving mainly
single cells organisms and mammalian cells, come
under the heading "presumptive," and Gary
Flamm of NCI summarized the state of the art in
that field of testing. Three categories of presump-
tive tests were outlined that are useful as predictors
ofcarcinogenesis or mutagenesis. The first assesses
the potential ofa substance and/or its metabolites to
damage and/or interact with DNA. The second cat-
egory is the mutational assay system in cultures of
single cells, such as bacteria, other microbial or-
ganisms, and mammalian cells. Here, mutational
changes are simply observed as indicators of the
carcinogenicity of the chemical. There are two
major classes to this category oftest: those in which
the cell responds to highly specific changes in its
DNA, and those which respond to any type of cel-
lular damage. Flamm reported that 85-90% of
known carcinogens are positive in the more prom-
ising single-cell tests system, the Ames test. But he
also reported that about 10% which show up as
positive have not been shown to be carcinogenic in
animal tests.
Said Flamm: "The extent of correlation depends
on what classes of chemical carcinogens we are
looking at. Chances are that if we looked at just
estrogens, we might find absolutely zero correla-
tion, whereas ifwe were looking at nitrosamines the
correlation might be 100o."
In other words, these tests can only be expected
to detect carcinogens which act directly on cellular
DNA. Indirect carcinogens, which induce cancer
by other mechanisms, may have little or no
mutagenic potency.
The final category reviewed by Flamm was neo-
plastic transformation, which measures the de-
velopment of neoplasms in normal cells grown in
tissue culture. Such cells when transplanted into the
appropriate host animals show all properties of
cancer cells. The problem, he said, is that these
cells are difficult to grow in tissue culture.
"Presumptive tests," he said, "will eventually
prove useful in providing additional evidence for
deciding upon marginal data on the carcinogenicity
or mutagenicity of a chemical derived from animal
experiments and in studying the interaction between
two or more substances. Additionally, they should
prove useful as research tools for investigating the
molecular targets of carcinogenicity, and in deter-
mining what specific events are obligatory to the
process of carcinogenesis. As knowledge accumu-
lates, the presumptive tests will provide useful in-
formation in the extrapolation of data from species
to species and from high dose to low."
But as S. Weinhouse of Temple University said
in his summary of the conference, "presumptive
tests are not yet ready to replace the costly, time-
consuming, uncertain assays in animals."
Reporting on the status of DNA repair as a pre-
sumptive indicator of resistance and susceptibility
to carcinogenesis, Ann Mitchell of Stanford Re-
search Institute concluded that many questions
need answering before the DNA repair approach
can be used as a viable tool. "In particular," she
said, "more extensive investigations are needed
before we can determine with confidence individual
variability, tissue specificity, or the potential
hazards of the large number of as yet untested
chemical agents."
Where does this leave the DNA repair approach
as a technique regulators can look to? Mostly as a
prescreen for identifying potentially hazardous
agents. Studies are underway to explore the pos-
sibilities of using DNA repair to correlate in vitro
and in vivo exposure, to correlate measurements of
DNA repair in animal systems with those in human
cells, to determine tissue susceptibility to various
hazardous agents, to monitor the effects of human
exposure to hazardous agents, and to predict the
individual variation in response to exposures. She
said an important potential lay in identifying high
risk subpopulations.
A vast amount of research still needs to be done
on the methodology itself before DNA repair can
contribute much to decision making at the policy
level. Adding to the methodological problem is the
enormous diversity among animals and humans in
the quality and level of their repair mechanisms.
Some systems repair more easily than others.
Some, through normal genetic variability, are defi-
cient in specific repair enzymes.
Animal-to-Man Extrapolation:
Report of Meselson Panel
Matthew Meselson of Harvard University was to
have reported to the conference on the animal-to-
man extrapolation study done by a National
Academy of Sciences subcommittee he headed as
part of a larger study on pest control practices and
prospects. He was unable to attend, and instead
Marvin Schneiderman of the National Cancer In-
stitute substituted with a highly abbreviated sum-
mary of Meselson's findings.
Meselson's panel phrased its major conclusion
this way: "Although there are major uncertainties
in extrapolating the results of animal tests to man,
this is usually the only available method for quan-
titative risk estimation. Despite the uncertainties,
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dose and time may operate and to provide rough
predictions of induced cancer rates in human popu-
lations."
Meselson's conclusion, said Schneiderman, was
that the best relationship between animal dose data
and human dose was a direct milligram per kilogram
relationship from the most sensitive animal species
to man. But there are some chemicals for which
man appears to be a very much less sensitive animal
than the most sensitive mammalian species. Yet,
the opposite can hold true for other chemicals.
Meselson thus raises the question ofwhether there
are some factors to use in establishing human safety
out of animal data.
Metabolic Variability among
Species
Richard Adamson of the National Cancer Insti-
tute provided a detailed overview of species-to-
species variation. There are the well acknowledged
internal and external variations in the response sus-
ceptibility ofanimals to toxic agents, as well as such
administration factors as route, volume, particle
size, vehicle composition, and dosage. But even if
all administration factors are held constant, species
still vary in response to foreign compounds-such
as differences in the way the animal absorbs, dis-
tributes, metabolizes, and excretes the compound.
He further reviewed the anatomical and
physiological differences, such as the absence ofthe
gall bladder in the rat, also the presence or absence
of viruses in the host animal. ("This is something
we tend to forget," he said. "We have inbred
C-type particles into the genome." And perhaps it's
the interaction between these compounds and the
virus, he indicated that may cause the cancer in the
animal. What can one believe from animal studies if
that is the case?)
The immune state of the animal, diet, and DNA
repairmechanism differences all come into play. He
presented data too showing the vast differences in
the rate of penetration of organophosphorus com-
pounds through the excised skin ofvarious species.
It differs about 30-fold among the pig, rabbit, and
rat.
Adamson's message was the need for better care
in experimentation and observation. His implica-
tion was that the human species is probably
stronger constitutionally than lower species and
probably more resistant to cancer. He said that the
incidence of liver cancer seems to have been drop-
ping despite the increase of chemicals in the envi-
ronment. But it was also pointed out in commentary
that other cancers are in fact on the increase, DDT
or not.
There was a swirl of other commentary on the
dubious advisability of "swamping" test animals
with high dosages of carcinogens. The modes of
action may be different at high dosages than at low
and can thus obscure not only the mechanism of
carcinogenesis but also introduce factors that may
be irrelevant to the natural conditions, where dos-
ages are usually low.
Further Differences in
Metabolism Within Species,
Within the Same Compound
There is distinct species differentiation in the way
animals handle metabolically different dosages of
the same and different compounds. R. T. Williams
of St. Mary's Hospital Medical School, London,
gave an extensive review of such differences.
Studies with such reference compounds as
phenylacetic acid, sulfadimethoxine, quinic acid,
coumarin, 4-hydroxy-3,5-diiodobenzoate, and
methanolhave shown overthe years that Old World
monkeys and occasionally New World monkeys are
similar to man in metabolic events that lead to
cancer. But the more species one studies, the more
complicated the picture tends to become.
With five arylacetic acids-phenyl-, p-chloro-
phenyl-, indol-3-yl-, and l-napththyl-man and the
rhesus monkey are similar. But the pattern ofconju-
gation depends on the arylacetic acid, since with
phenyl-, p-chlorophenyl-, and indolyl acetic acids,
the main conjugate in both species is the expected
glutamine conjugate. But with 1-naphthylacetic acid,
the glucuronic acid conjugate is formed, and with
p-nitrophenylacetic acid, no conjugate at all is
formed in either species.
It is indeed complex, and the metabolic
taxonomy grows and grows. High dose and low
dose metabolism differs significantly too. "In gen-
eral," he said, "it seems probable that the extent of
metabolic pathways will change with increase in
dose, since it is to be expected that different
mechanisms have different capacities. And fur-
thermore, some compounds can induce their own
metabolism and possibly one pathway more than
another."
Significance of Time in
Extrapolation
Daniel Zaharko of the National Cancer Institute
introduced a concept that he said was usually over-
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data to man. It is not sufficient, he said, simply to
extrapolate animal concentration levels for a
reasonably accurate assessment of the drug's be-
havior in man. Time is an equally important vari-
able. By time he meant the rate at which the chemi-
cal is admitted and metabolized. These rates differ
drastically from species to species, as obviously
does metabolism itself.
Thus, the importance of proper scaling from
species to species is a frequently neglected factor.
"There are scientific reports that continue to
criticize toxicity studies in small animals as being
not relevant to man because of the much larger
doses used in animals," he said. Moreover, there is
a lack ofappreciation for the higher metabolic rates
and higher clearances that generally exist in ex-
perimental animals. Other factors affecting delivery
to intracellular compartments are blood flow, mix-
ing volume, membrane permeability, and binding.
Zaharko in his research used computer models to
simulate such factors and give insight into their re-
lative significance in determining concentration and
exposure time at the actual site of action.
If concentrations at the active site can be pre-
dicted and ifbiochemical mechanism is known, then
ways ofcounteracting the effect may be developed.
When environmental exposure is inevitable, use of
another substance to protect against toxicity could
be effective.
Diversity in Susceptibility to
Cancer in Human Beings
Louise Strong ofthe University of Texas School
of Medicine reviewed the wide range ofsusceptible
subgroups within the human population to various
cancers and various carcinogens. Chromosomal in-
stability, genetic variability, and different types of
physiological disorders all influence environmental
susceptibility. Too, environmental agents as well as
radiation could induce an existing predisposition to
activation. "Any factor, endogenous or exoge-
nous," she said, "including growth stimulating
factors, hormones, drugs, depressed immune sys-
tem, etc., which might give the mutant cell an ad-
vantage may increase the probability of malig-
nancy."
Study ofsubgroups susceptible to carcinogenesis,
she indicated, and definition of the mechanism of
their susceptibility is critical to any attempt to ex-
trapolate datafrom animal to man or from high dose
to low dose response. "Even if carcinogenesis can
be reduced to a simple two-step mutational model,
man is not homogenous with respect to mutation
rates, elimination of mutant cells, growth control,
metabolism ofpotential mutagens, or the number of
mutational steps necessary for malignancy," she
said. "Study ofeach uniquely susceptible subgroup
may contribute to our understanding of car-
cinogenesis in general, and may provide com-
plementary in vitro systems for the evaluation of
potential mutagens."
Strong's paper further increases the sense of
complexity that permeates the field of research
leading to standards development. She pointed out
in considerable detail the many variations of
susceptibility-so diverse as to be virtually beyond
the limits ofpublic health authorities to fully protect
everyone in any given community. With so many
persons susceptible in so many potential ways, the
"average person" protected by a consensus stan-
dard becomes unknowable.
Can the Complexities be
Simplified?
While Strong presented an inventory ofthe many
faces of variability in susceptibility, W. W. Weber
of the University of Michigan used one class of
chemicals, the aromatic amines, to illustrate further
the problems of extrapolating carcinogenic data
from animals to man. "There is new knowledge de-
rived from biochemistry, molecular biology, micro-
bial and human genetics, and pharmacology, and
from various levels of biological organization that
mustbe organized from predictingrisks to man," he
said.
No one species can serve as the model for
metabolism of all compounds in humans. Many
reactions are involved in the transformation of an
environmental chemical to a carcinogen. For exam-
ple, aminofluorine becomes acetylaminofluorene
(AAF), and AAF is probably not the ultimate car-
cinogen, whatever the species. Very little, Weber
said, has been reported on the range ofvariability in
deacetylation in the metabolism of carcinogens.
It may be possible at some future time to deter-
mine human susceptibility to environmental car-
cinogens, he pointed out. The human population
may be divided genetically into rapid acetylators
and slow acetylators, using isoniazid as a tracer
compound. "It seems," he mused, "that people
who are genetically rapid acetylators of isoniazid
might also be expected to transform aminofluorene
and other hazardous amines to activated car-
cinogenic forms more rapidly than slow
acetylators." Weber and his group are studying the
problem.
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David Clayson said science simply has not pro-
gressed to the point of having sufficient details to
make assured species-to-species extrapolations.
The latency periods (elapsed time from first expo-
sure to clinical manifestation of the disease) differ
between mice and men. These are vast differences,
and what is more, they are poorly understood.
Clayson said it was necessary to break the car-
cinogenic process down to its "constituent parts"
before valid extrapolations can be made across
species boundaries. "I don't feel nihilistic," he
said, "but I feel that research on the activities ofthe
proximate carcinogens needs to be done. The
quantification ofthese factors will entail agreat deal
of work with each carcinogen in each tissue. This
effort has been largely ignored by cancer re-
searchers who have apparently more exciting things
to do."
But the problem, he said, is that the work will
take many tens ofthousands ofanimals to establish
the carcinogenic response down to dose curves at
the 1% level. "More theoretical considerations may
have to be used to establish acceptable carcinogenic
risk levels to a relevant level ofone in 106 to one in
108 because the cost of direct experimental ap-
proaches would be prohibitive," he concluded.
mind of thinking that when we reduce the levels of
exposure to below 1/1,000 ofthe level that will pro-
duce measurable experimental results in animals in
the latter half of their life span, the theoretical
tumors we can calculate on the basis of underlying
molecularchain ofevents will not happen during the
animal's lifetime-probably not for five lifetimes."
Jones did concede the need to do considerably
more research to provide a verifiable data base for
the human exposure to chemicals-not just radia-
tion. "The big problem is that we don't have the
money or the resources to resolve these issues," he
said.
The notion of "practical thresholds," introduced
by Hardin Jones, was criticized by Elizabeth Scott
of the Statistics Department, University ofCalifor-
nia at Berkeley. She said it amounted to equating
small risks with zero risks. The fact that the ex-
pected time-to-tumor, conditional on not having
died from a competing cause ofdeath, may be far in
excess of usual animal lifespans just reflects a low
probability of developing a tumor before dying of
something else. The extrapolation problem involves
estimating these probabilities. Similar objections
were voiced by Richard Peto ofOxford University.
He said his analysis ofthe same data had led him to
conclusions different from those which Hardin
Jones had drawn.
Significance of Time in Low Dose Extrapolation: The Mathematical
Effects: the Latency Period Approaches
A major focus of controversy in the debate over
environmental carcinogenesis and establishment of
standards is whether time, or the latency period will
nullify the carcinogenicity of chemicals in small
doses. Hardin Jones of the Donner Laboratory of
the University ofCalifornia at Berkeley, discounted
concern over cancer from low dose levels by re-
search data showing that the cube root ofthe dose is
inversely proportional to the time-to-tumor. That
means, said Jones, that there can be assumed to be
''practical thresholds," relating concentration to
the time expected before neoplasms form. "Ifthey
occur beyond the lifespan," he said, "the cost is nil
because a practical threshold ofeffect has not been
exceeded."
Jones drew on data from radiation effects on
workers who manufactured watches containing
dials made ofradium and on the atomic bomb casu-
alty data. Both sets of research, he said, followed
the cube-root law.
"If we take seriously the things I said about
time," he said, "then the extrapolations of known
carcinogens to very low doses give us the peace of
Before resuming this general account of the ex-
trapolation conference a small primer on the
mathematical approaches is in order. This is a de-
scription of some ofthe mathematical bases for risk
extrapolation, taken directly from the report on
Contemporary Pest Control Practices and Pros-
pects from the National Academy of Sciences:
Threshold Hypothesis
The threshold hypothesis assumes that there is a
dose below which cancer induction cannot occur.
An examination ofpublished dose response data for
chemical carcinogenesis in laboratory animals pro-
vides no clear indication of a threshold for any car-
cinogen. In a review of 151 dose-response curves,
none was found to be clearly inconsistent, in a man-
ner suggesting a threshold, with both the single
event and the probit hypotheses discussed below.
Neither is there any adequate theory of chemical
carcinogenesis that would require the general exis-
tence of thresholds. Thus, even if a threshold is
postulated, there is presently no empirical or
February 1978 177theoretical basis fordetermining the dose at which it
may occur. Unless and until this can be done, the
threshold concept does not provide a practical basis
for risk estimation.
Single-Event Hypothesis
The single-event hypothesis assumes that the in-
duced incidence ofcancer is directly proportional to
the dose, all the way from the lowerincidence levels
that can be measured in animal experiments of
practical size down to zero dose and zero response.
In other words, below an induced incidence of
about 10%, the dose-response curve is, for practical
purposes, a straight line. This would result, for
example, if cancer is induced by a single cellular
event, the likelihood of which is directly propor-
tional to the dose of carcinogen. An essentially
linear dose-response relationship can also result
under much more general assumptions, so long as
the carcinogen in question simply adds its effects to
those of other carcinogens already present.
The single-event hypothesis is in agreement with
the limited data available for man. The induction of
leukemia by ionizing radiation from nuclear explo-
sions is compatible with a linear dose response
down to an induced incidence of about 0.1%, the
lowest incidence for which the available data can
meaningfully be analyzed. Other data on the induc-
tion of various types of cancer following radiation,
although less extensive, are likewise compatible
with linearity. The dose response relating the inci-
dence oflung cancer in man to the average number
ofcigarettes smoked perday is alsocompatible with
the single-event hypothesis. In this case, the data
can be analyzed down to an induced incidence of
approximately 2%.
Animal experiments are notusually conducted on
a scale large enough to measure induced incidence
below afew percent. For some carcinogens in some
investigations, the dose-response relation is com-
patible with the single-event hypothesis, while in
other cases it is not. However, it is quite possible
that a dose-response departing from the single-
event hypothesis at high induced incidence may
nevertheless converge to a linear relation at lower
incidence values.
Probit and Other Hypotheses Implying
a Dose-Response Curve That Is
Concave Upwards
This class ofhypotheses assumes that there is no
threshold for a population but that the incidence at
doses below the lowest tested is less than that im-
plied by the single event hypothesis. Below a re-
sponse of a few percent, such a relationship be-
tween dose and response is described by a smooth
curve that is concave upwards. For example, the
incidence ofskin tumors produced by surface appli-
cation of benzo[a]pyrene in the mouse has been
found to vary as the square ofthe amount ofchemi-
cal applied over the dose range examined.
Another dose-response relation that is concave
upwards at low dose levels is the probit curve. It
assumes that the sensitivity of individuals in a
population to chemical carcinogenesis is a gaussian
function of the logarithm of the dose. The probit
dose-response curve is S-shaped, with a slope that
at first increases and then decreases as the dose is
lowered. Its use requires the choice ofan adjustable
parameter, the probit slope, that describes the nar-
rowness of the presumed gaussian distribution of
sensitivity to carcinogenesis in the population at
risk.
The probit slope may be estimated from dose-
response data at high incidence, as determined in
an animal experiment, so long as the experimental
data is compatible with a probit curve. For suffi-
ciently low dose levels, the probit extrapolation al-
ways predicts a lower incidence than does the
single-event hypothesis. However, for a value for
the slope that is well in the range ofvalues found for
various carcinogens in animal experiments at high
incidence, the probit extrapolation for lower doses
does not differby more than a factor often from the
incidence predicted by the single-event hypothesis
down to an induced incidence of about one per
100,000 exposed individuals.
Estimates of Carcinogenic Hazard
Until more is known about the mechanisms of
chemical carcinogenesis, any method of extrapola-
tion to predict cancer rates at doses much lower
than tested will remain partly a matter of conjec-
ture. However, the single-event hypothesis proba-
bly provides an upper limit for induced incidence
estimates at low dose levels and is compatible with
the very limited human data on carcinogenesis at
intermediate response levels. It would therefore
seem prudent to employ the single-event hypothesis
in making risk estimates, at least for those carcino-
gens forwhich the dose-response curve from animal
experiments approaches linearity at the lower re-
sponse levels that can practically be studied. In that
case, the estimated total lifetime incidence in man
resulting from continuous exposure to an environ-
mental carcinogen would be the lifetime incidence
Environmental Health Perspectives 178for continuous exposure to the same total dose per
body weight found by extrapolation of the animal
data under the single-event assumption. For risk
assessment, the resulting estimate would then be
subject to adjustment to allow for statistical uncer-
tainty in the input data.
Cancer Age Distribution Is
Dose-independent and
Risk Is Dose-Proportional
Richard Peto of Oxford University proposed a
pair of statistical dogmata which he said should be
the foundation forregulatory action. The first stated
that at low dose rates, the age distribution of extra
tumors beyond those expected from background
causes is independent of dose rate. That is, fewer
extra tumors would occur at low dose rates than at
high dose rates, but the ratio of the total extra
tumors to the extra tumors occurring before age 50,
for example, would be the same at low dose rates as
at high dose rates. Second, that at low dose rates
the expected numberofextra tumors is proportional
to the dose rate.
"There may be a few exceptions to my conclu-
sions," he said, "but the arguments are very gen-
eral and so regulatory agencies should, in any par-
ticular case, expect this dogma to apply unless they
have specific evidence that, in the particular case
that interests them, the dogmas are false. Because
of the wild, outbred heterogeneity of humanity,
even agents with threshold-type action in most indi-
viduals will also probably comply with the dogma."
There are two main objections to his dogma, Peto
said. The first assumes thresholds exist, while the
dogmas say that they effectively do not, because
"background" carcinogens are persistent and are
increasing at rapid rates. Thus, when toxicologists
debate what concentration between zero and 1020
molecules is safe, they disregard the fact that 1020
molecules may already exist as background.
The second objection, said Peto, states that when
high dosages of carcinogens are given to animals,
the time T50 until half the animals have cancer is
roughly proportional to d&'3. This has led to the
hope," he said, "that at low enough dose levels
almost all tumors would occur long after age 100,
and so would be irrelevant to the human condition.
The point is that doses given in these experiments
were so high that each animal would have de-
veloped several tumors during its natural lifespan,
each with a similar age distribution. While the ex-
pected time, or latency period, would increase with
decreasing dose, this would not continue indefi-
nitely. Ifthe expected number oftumors per animal
is only 0.1, for example, then so few animals would
get two or more tumors that the effects of the first
tumor obscuring later tumors will be negligible.
Because ofthe statistical uncertainties in the dif-
ferences between the numbers oftumors found in a
control group ofanimals and a treated group ofani-
mals, cancer risks lower than about 10o cannot be
accurately characterized, even by large experi-
ments.
Statistical Approaches:
Different Models Yield Markedly
Different Extrapolations
Charles Brown of the National Cancer Institute
looked at the statistical uncertainties associated
with low dose risk extrapolations. Uncertainty has
two main statistical origins, he reported, sampling
variability and the more common uncertain choice
of a specific dose-response model. He showed that
a wide range of low dose extrapolations, spanning
several orders of magnitude, can be considered
statistically consistent with a given set of dose-
response data from tests in the high dose range.
Experimental data on dimethylnitrosamine in
female rats were used to illustrate his points.
In this paper, Brown introduced the key point
that models which appear to fit the data well in the
high dose range can still yield low dose extrapola-
tions differing by several orders of magnitude, de-
spite their agreement at high doses.
"Use of a general muliparameter model is one
approach that should give good fits to most experi-
mental data and would lead to variability estimates
that include both sampling and model-specific vari-
ation," he concluded.
Low-Dose Linearity Cannot Be
Ruled Out Statistically, Even By
Large-Scale Experiments
Using a multiparameter model of the type men-
tioned by Brown, Harry Guess of NIEHS and
Kenny Crump of Louisiana Tech University
analyzed animal data for the chemical carcinogens
vinyl chloride, dieldrin, DDT, and dimethylni-
trosamine and for ionizing radiation. Their aim was
to resolve the controversy between probit and
single-event extrapolation by using a model general
enough to admit both dose-response curves in
which risk is proportional to dose in the low-dose
range (as in the single event model) and curves in
which risk decreases much more rapidly with de-
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set of data their computer program calculates the
dose-response relationship under which the ex-
perimental results have the highest probability and
also calculates upper confidence limits on risk as a
function of the dose.
They found that the "most likely" dose-response
relations for these chemical carcinogens as well as
for ionizing radiation are linear at low doses. In
addition, they used computer simulations to con-
clude that it appears extremely unlikely that even a
large-scale experiment involving several thousand
animals per dose could conclusively rule out the
possibility that the dose-response curve becomes
approximately linear in the range of risk below
about one percent.
"And when background is present," they said,
"it is all but impossible to reject the hypothesis of
near linearity at low doses. For example, by
changing the outcomes of only 11 out of8,000 ani-
mals in a set ofdata it is possible to change the form
of the best-estimate dose-response relation from
one that is highly nonlinear to one that is approxi-
mately linear at low doses. This implies that the
upper confidence limits on risk will virtually always
be linear at low doses, even though the best esti-
mates may be highly nonlinear."
"Our results have implications which should be
considered by anyone who intends to design a large
scale experiment to measure the shape of dose-
response curves for chemical carcinogens in very
low dose ranges. When both very flat curves and
gradually sloping curves are considered together, it
is extremely difficult on mathematical grounds
(even with nearly perfect data) to reject the
hypothesis that the dose-response curve is nearly
linear in the dose range corresponding to increased
risks over background of about 10- or less."
Verification of Linearity at Low
Dose by Radiation Experiments
Charles H. Nauman and Arnold H. Sparrow of
Brookhaven National Laboratory described experi-
ments on plant mutations using ionizing radiation
and gaseous forms of several suspected chemical
mutagens. Their study showed that adose-response
curve for mutational response could be linear at low
doses and nonlinear at high doses. These results
showed that if only the high dose data had been
considered and the dose-response curve had been
extrapolated graphically on log-log paper into the
low dose range, the mutagenic potential ofthe radi-
ation would have been underestimated. Results
with the chemicals were considerably more scat-
tered.
R. Lowry Dobson of Lawrence Livermore
Laboratory presented some early results on the
biological effects of tritium at low levels and con-
cluded that the biological effectiveness of this in-
sufficiently studied substance does not change
appreciably with dose or dose rate.
He found, on the basis of studies with animal
oocytes, that the relative biological effectiveness of
tritiated water is higher for low level, protracted
exposure than for short, higher levels. He said it
also seemed possible to extrapolate from short-
exposure to tritiated water to chronic exposure.
"The possibility has not been excluded," he said,
"that a significant degree of especially effective
subcellular microdistribution of tritium atoms may
occur with protraction of exposure.'"
Contributions to Extrapolation
from Epidemiology
Observation and measurement of the effects of
toxic chemicals on workers exposed to them over
several years can be of invaluable help assembling
the statistical data needed for reliable extrapolation.
P. Enterline ofthe University ofPittsburgh studied
the results ofasbestos exposure affecting 17,800 as-
bestos workers. Again, the results were to cast
doubt on the easy assumption thatthresholds canbe
a basis for setting numerical standards.
He not only verified that very little difference
exists in the effects between a single year's expo-
sure and continuous exposure; he also showed that
there remains significantly increased cancer risks
for asbestos exposure below the current occupa-
tional health standard. "The current regulatory
limit value for asbestos is 5 fibers per cubic cen-
timeter (f/cc) averaged over an 8-hr day, not to ex-
ceed 10 f/cc at any one time," he reported. "As is
true for most standards, no epidemiological data on
factory workers exposed at this level are available.
Ourmodel shows that4 f/cc predicts a20% increase
in respiratory cancer among factory workers after
40 yr and a 40% increase after 60 yr. His model
consisted of a series of assumptions based on past
data gathered on asbestos toxicology.
Peter Infante, substituting for Joseph Waggoner
of the National Institute for Occupational Safety
and Health, reviewed a series of data relating
epidemiologic studies of vinyl chloride and a
number of anesthetics to high incidences of cancer
and birth defects. In doing so, he asserted that
epidemiologic data have not been given strong
enough emphasis in determining the safety of toxic
substances.
"The epidemiological approach for mutagenesis
or teratogenesis," Infante said, "being the equiva-
Environmental Health Perspectives 180lent of short-term in vitro or in vivo tests, can be a
useful testforcontrolling many carcinogens without
waiting for the long latent period socharacteristic of
occupationally induced cancer."
Thresholds
There are two ways of looking at thresholds for
carcinogens: with the scientific fascination of the
molecular researcher, and with the view ofthe reg-
ulatory official who needs answers quickly. The
scientific facts were reviewed by Hans Falk of
NIEHS and the more philosophical facts and policy
implications by David Rall, also of NIEHS.
Determination of thresholds are terribly compli-
cated, Falk said, and elaborated. "Thresholds can
be moved backandforth by anumberoffactors that
are temporal in nature. In other words we may be
having this threshold today and that threshold to-
morrow on the basis of either intercurrent disease,
dietary splurges, or exposures to other chemicals
that may help in this process."
He said consideration of thresholds would have
to take into account the fact of deactivating
mechanisms that normally occur in the organism.
Enzymes such as glutathione transferase deacti-
vate carcinogens. "This is not an imaginary reac-
tion that we can put on any blackboard for the sake
of saying what could happen. This does happen."
Falk outlined the highlights ofrepair mechanisms
and further outlined the complexities of the car-
cinogenic process. "Many of the mutations that
may be produced by a chemical may not be terribly
significant," he said. "It is not the fate of most
molecules to end up as active carcinogens, particu-
larly at minute dose levels."
But those that do, or that might, are the concern,
and scientific facts and informed speculation must
lead to regulatory action. Scientifically, thresholds
are fascinating, said Rall. But as a basis for policy
decisions over standards, he had doubts.
Each new chemical that is added to the environ-
ment introduces that much more added risk, he
said, notwithstanding the fact that some chemicals
may neutralize the carcinogenic potential of other
chemicals. The main issue, he said, was over the
long term effects of today's chemicals.
Carcinogenic effects are irreversible, he said.
Even removing a chemical from the environment
will not reverse the carcinogenic process once it has
been triggered by that chemical. It is perfectly logi-
cal, said Rall, to believe that low concentrations of
even the most potent carcinogens will not cause
cancer. "But to design an experiment to show
whether or not such a statement is correct would
take enormous resources and, even if the experi-
ment could be performed, the answer would proba-
bly be suspect," he said.
The human population is diverse and thresholds
should reflect that diversity. There is no one
threshold that would cover the public. The issue,
then, is not really thresholds, he said, but one of
adding new carcinogens to the pool of carcinogens
already present in the environment.
"If thresholds do exist and the regulatory deci-
sions are based on a no-threshold concept there will
be short-term economic losses," he said. "If
thresholds do not exist and the regulatory decisions
are based on thresholds, then there will be fewer
short-term economic losses. But we would face a
future of damaged human somatic and germinal
DNA and an increased incidence of neoplastic dis-
ease."
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